Global Pemphigus Vulgaris Market

Pemphigus Vulgaris Market Summary, Size & Emerging Trends

According to Decision Advisor, The Global Pemphigus Vulgaris Market Size is Expected to Grow from USD 479.6 Million in 2024 to USD 1121.2 Million by 2035, at a CAGR of 8.03% during the forecast period 2025-2035. Rising prevalence of autoimmune diseases and increasing adoption of targeted therapies are key driving factors for the pemphigus vulgaris market.

Key Market Insights

• Asia Pacific is expected to account for the largest share in the pemphigus vulgaris market during the forecast period.
• In terms of therapy type, the Anti-CD20 monoclonal antibodies segment is projected to grow the fastest due to advances in biologics.
• In terms of distribution channel, hospital pharmacies dominated the market share owing to higher accessibility and treatment availability.

Global Market Forecast and Revenue Outlook

• 2024 Market Size: USD 479.6 Million
• 2035 Projected Market Size: USD 1121.2 Million
• CAGR (2025-2035): 8.03%
• Asia Pacific: Largest market in 2024
• North America: Fastest growing market

Pemphigus Vulgaris Market

The pemphigus vulgaris market revolves around therapies for an autoimmune blistering disorder characterized by painful mucosal and skin lesions. Treatment focuses on immune suppression to reduce antibody production against skin cell adhesion proteins. Anti-CD20 monoclonal antibodies such as rituximab have revolutionized treatment by targeting B cells, offering better efficacy and safety profiles compared to systemic corticosteroids. Hospital pharmacies serve as primary distribution points due to the specialized nature of treatments requiring close monitoring. Increasing awareness, early diagnosis, and development of novel therapies are fueling market growth globally.

Pemphigus Vulgaris Market Trends

• Increasing preference for biologics over conventional corticosteroids to minimize side effects.
• Growing investments in research for targeted therapies and personalized medicine.
• Expansion of hospital pharmacy networks to improve treatment accessibility.

Pemphigus Vulgaris Market Dynamics

Driving Factors: Rising incidence of autoimmune diseases and adoption of novel therapies

Pemphigus vulgaris is an autoimmune disorder where the body’s immune system mistakenly attacks the proteins holding skin cells together, causing painful blisters and sores. The global incidence of autoimmune diseases, including pemphigus vulgaris, is increasing due to factors such as genetic predisposition, environmental triggers, and better disease awareness. Improved diagnostic technologies now allow for earlier and more accurate detection, which means more patients are getting diagnosed and treated. This rise in diagnosis naturally increases demand for effective treatments.

Restrain Factors: High treatment costs and limited access in developing regions

One major barrier to market growth is the high cost of biologic therapies like Anti-CD20 monoclonal antibodies. These therapies involve complex manufacturing processes and require cold-chain logistics, which increase overall expenses. As a result, many patients, especially in low- and middle-income countries, find these treatments unaffordable or inaccessible. Furthermore, healthcare infrastructure in many developing regions is still inadequate, limiting availability of specialized care and treatment monitoring needed for these therapies.

Opportunity: Development of biosimilars and expansion of distribution networks

Biosimilars are nearly identical, lower-cost versions of existing biologic drugs (like Anti-CD20 monoclonal antibodies). Their development can significantly reduce treatment costs and expand access, especially in price-sensitive markets. As patents expire on original biologics, biosimilars are entering the market, creating a competitive environment that encourages affordability. Moreover, retail pharmacy chains in emerging markets are growing rapidly, providing wider and more convenient access to topical therapies and systemic corticosteroids. This expansion opens new distribution channels beyond traditional hospital pharmacies, helping reach patients in more remote or underserved areas.

Challenges: Regulatory approvals and supply chain disruptions

Launching new therapies involves stringent regulatory processes to ensure safety and efficacy. These approval procedures can be lengthy and costly, delaying time-to-market for innovative treatments. Regulatory disparities across countries can further complicate global market expansion for pharmaceutical companies. Supply chain disruptions pose additional challenges. Geopolitical tensions, pandemics (such as COVID-19), and logistical issues can interrupt the production and distribution of critical medications, leading to shortages or delays.

Global Pemphigus Vulgaris Market Ecosystem Analysis

The ecosystem comprises key pharmaceutical manufacturers producing monoclonal antibodies and corticosteroids, distribution networks including hospital and retail pharmacies, healthcare providers specializing in autoimmune dermatology, and regulatory agencies enforcing drug approvals. Collaboration between these stakeholders is crucial to ensuring steady supply, advancing research, and improving patient outcomes.

Global Pemphigus Vulgaris Market, By Therapy Type

What factors enabled the Anti-CD20 monoclonal antibodies segment to lead the pemphigus vulgaris market in 2024?

The Anti-CD20 monoclonal antibodies segment dominated the pemphigus vulgaris market in 2024 by capturing approximately 60% of the market share due to its high efficacy in targeting B-cells involved in disease progression, a strong safety profile compared to conventional therapies, and growing adoption supported by favorable clinical outcomes. Additionally, increasing awareness among healthcare providers and patients, along with ongoing advancements in antibody technology, provided this segment a significant competitive edge, making it the preferred choice over other therapeutic options during the forecast period.

Why did the systemic corticosteroids segment maintain a strong presence in the pemphigus vulgaris market in 2024?

Systemic corticosteroids continued to hold a significant market share of about 35% in 2024 due to their established efficacy in rapidly controlling inflammation and symptoms in pemphigus vulgaris patients. Despite the rise of newer therapies, corticosteroids remain widely used because of their accessibility, cost-effectiveness, and well-understood treatment protocols. Additionally, many clinicians still rely on corticosteroids either as a primary treatment or in combination with other therapies, ensuring their sustained presence in the market during the forecast period.

Global Pemphigus Vulgaris Market, By Distribution Channel

How did hospital pharmacies gain a competitive edge in capturing the largest revenue share in the pemphigus vulgaris market in 2024?

Hospital pharmacies accounted for the largest revenue share, approximately 70%, in the pemphigus vulgaris market in 2024 due to their direct access to patients requiring specialized treatment and their ability to provide immediate and comprehensive care. Hospitals are often the primary point of diagnosis and treatment initiation for Pemphigus Vulgaris, leading to higher medication dispensation through hospital pharmacies. Furthermore, hospital pharmacies benefit from strong relationships with healthcare providers and the ability to manage complex therapies, making them the preferred distribution channel during the forecast period.

What made retail pharmacies a key distribution channel in the pemphigus vulgaris market in 2024?

Retail pharmacies held a significant share of around 30% in the pemphigus vulgaris market in 2024 due to their widespread accessibility and convenience for patients, especially for ongoing medication refills and outpatient care. Their extensive network allows patients to easily access therapies closer to home, contributing to patient adherence and satisfaction. Additionally, retail pharmacies often provide personalized services and counseling, making them an important channel alongside hospital pharmacies in the distribution of Pemphigus Vulgaris treatments during the forecast period.

Asia Pacific is anticipated to hold the largest share of the pemphigus vulgaris market, accounting for approximately 45% of global revenue.

This dominance is driven by increasing awareness of autoimmune diseases, improving healthcare infrastructure, and rising availability of advanced therapies such as Anti-CD20 monoclonal antibodies. Countries like China, India, and Japan are witnessing growing investment in healthcare and diagnostics, facilitating early detection and treatment. Additionally, expanding government initiatives and insurance coverage improve patient access to costly biologics in this region.

North America is expected to register a significant CAGR, capturing about 30% of the market.

The region benefits from well-established healthcare systems, high adoption of innovative therapies, and extensive research and development activities. The United States, in particular, is a key market with a strong presence of pharmaceutical companies and clinical trials focused on novel pemphigus vulgaris treatments. Advanced reimbursement policies and patient support programs further boost market growth here.

Europe holds a stable share of around 20% in the pemphigus vulgaris market.

The presence of robust healthcare infrastructure, favorable reimbursement frameworks, and increasing prevalence of autoimmune diseases support market expansion. Western European countries such as Germany, the UK, and France lead adoption of advanced biologics. However, market growth in some Eastern European countries may be restrained due to limited healthcare budgets and infrastructure gaps.

WORLDWIDE TOP KEY PLAYERS IN THE PEMPHIGUS VULGARIS MARKET INCLUDE

• • Roche (Rituximab)
  • Novartis
  • Sanofi
  • Pfizer
  • Mylan
  • Lupin
  • Sun Pharmaceutical Industries Ltd.
  • Others

Product Launches in Pemphigus Vulgaris Market

• In July 2023, Roche made a significant advancement in the pemphigus vulgaris treatment landscape by launching a biosimilar Anti-CD20 monoclonal antibody specifically targeting this autoimmune disorder. This launch represents a strategic effort to provide a more affordable alternative to existing biologic therapies, which are often associated with high treatment costs. By introducing a cost-effective biosimilar, Roche aims to increase patient access to advanced, targeted treatments that offer improved efficacy and safety profiles.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Decision Advisor has segmented the pemphigus vulgaris market based on the below-mentioned segments: 

Global Pemphigus Vulgaris Market, By Therapy Type

• • Anti-CD20 Monoclonal Antibodies
  • Systemic Corticosteroids
  • Topical Therapies

Global Pemphigus Vulgaris Market, By Distribution Channel

• • Hospital Pharmacies
  • Retail Pharmacies

Global Pemphigus Vulgaris Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa

FAQs

Q: What is the market size of the Global Pemphigus Vulgaris Market in 2024?
A: The Global Pemphigus Vulgaris Market size was estimated at USD 479.6 million in 2024.

Q: What is the forecasted CAGR of the Global Pemphigus Vulgaris Market from 2025 to 2035?
A: The market is expected to grow at a CAGR of 8.03% during the period 2025–2035.

Q: What is the projected market size of the Global Pemphigus Vulgaris Market by 2035?
A: The Global Pemphigus Vulgaris Market size is forecasted to reach USD 1121.2 million by 2035.

Q: Which region is expected to hold the largest market share in the Pemphigus Vulgaris Market?
A: Asia Pacific is expected to account for the largest share in the Pemphigus Vulgaris Market during the forecast period.

Q: Which therapy type segment is projected to grow the fastest in the Pemphigus Vulgaris Market?
A: The Anti-CD20 monoclonal antibodies segment is projected to grow the fastest due to advances in biologics.

Q: Which distribution channel dominated the Pemphigus Vulgaris Market in 2024?
A: Hospital pharmacies dominated the market share, accounting for approximately 70% of the revenue in 2024.

Q: What are the key factors driving growth in the Pemphigus Vulgaris Market?
A: Rising prevalence of autoimmune diseases and increasing adoption of targeted therapies are major market growth drivers.

Q: What challenges are limiting the adoption of Pemphigus Vulgaris therapies?
A: High treatment costs, limited access in developing regions, stringent regulatory approvals, and supply chain disruptions are key restraints.